Shanzha Mammary Perfusion Solution Veterinary Grade API is a standardised botanical active substance derived from the fruit of Crataegus pinnatifida Bunge, assigned manufacturer model code SZ-MPS-VG-25. The material is released as a filtered aqueous ethanolic extraction, with a dry matter content of not less than 20% w/w and a pH range of 4.0–5.5 when measured by USP 791. It is intended solely for further manufacture of veterinary medicinal products in the dosage forms of tablets, injections, capsules, powders, granules, premix, and solutions. The extraction vehicle is ethanol 30–50% v/v in purified water; after extraction, the liquid is clarified, passed through a 0.2 µm polyethersulfone membrane, and filled under nitrogen into high-density polyethylene drums. Each batch is identified by extraction ratio, batch number, manufacture date, retest date, and storage condition of 15–25°C protected from light. The marker substances chlorogenic acid and hyperoside are quantified by high-performance liquid chromatography with diode-array detection; identification is confirmed by thin-layer chromatography and retention-time agreement. Standardisation on an anhydrous basis, with a hyperoside-to-chlorogenic acid ratio of 0.45–0.65, is applied to reduce lot-to-lot variation in final veterinary dosage forms.

The solution is not sold as a finished dosage form and does not carry a sterility claim in the bulk API grade. For manufacturers compounding intramammary infusion products, the solution must be further diluted, pH-adjusted, and sterilised according to the approved marketing authorisation. Published efficacy data for this specific botanical configuration is limited; therefore, clinical dosing must be derived from the product-specific veterinary dossier rather than from human pharmacopoeial monographs.

Which Compendial Release Criteria Govern This Veterinary-Grade API?

Compendial release testing follows current editions of USP, Ph. Eur., and ICH guidelines. Identification is carried out by thin-layer chromatography per Ph. Eur. 2.2.27 and by HPLC-DAD retention-time agreement. Assay of chlorogenic acid and hyperoside is performed by HPLC-DAD using external reference standards; the batch release specification requires both markers within 90–110% of the stated content. Residual solvents are determined by headspace gas chromatography using USP 467 Option C, with compliance to ICH Q3C Class 3 limits only. Ethanol, if present as the primary solvent, is controlled to not more than 5000 ppm in the as-supplied liquid, methanol not more than 3000 ppm, and isopropanol not more than 5000 ppm. Elemental impurities are assessed by inductively coupled plasma mass spectrometry according to USP 232 and USP 233; the limits follow the oral and mucosal route permitted daily exposure values in ICH Q3D. The material is tested for lead, cadmium, arsenic, and mercury by atomic absorption, with typical values below 1 ppm each; the certificate of analysis is the binding document for each lot.

Microbial enumeration is performed by USP 61 and specified organism absence by USP 62. The non-sterile API acceptance criteria require total aerobic microbial count not more than 10³ CFU/g, total yeast and mould count not more than 10² CFU/g, and absence of Escherichia coli, Salmonella, and Staphylococcus aureus. For injectable-grade manufacture, bacterial endotoxin is controlled according to USP 85 or Ph. Eur. 2.6.14, with an action limit not more than 0.5 EU/mL in the filtered solution. Sterility testing of the bulk API is not claimed; the finished injectable or perfusion solution must be terminally sterilised or aseptically filtered and tested by the licensed manufacturer under USP 71 or Ph. Eur. 2.6.1.

Solution clarity is assessed by visual inspection against black and white backgrounds and controlled by nephelometry with a requirement of not more than 20 NTU. Relative density is determined by USP 841 and is controlled at 1.02–1.08 g/cm³ at 20°C. Refractive index is 1.35–1.38 at 20°C. Viscosity is measured by a Brookfield rotational viscometer at 25°C and is typically 5–20 mPa·s. Non-volatile matter by USP 731 is not less than 20% w/w. The assigned retest period is 36 months from manufacture in unopened high-density polyethylene containers stored at 15–25°C protected from light. After opening, the manufacturer should retest for microbial enumeration and pH within 7 days if stored at 2–8°C.

During tablet manufacture, the liquid API is most commonly used as the granulating fluid. A high-shear mixer-granulator is charged with lactose monohydrate, microcrystalline cellulose, and crospovidone, and the Shanzha solution is sprayed at 8–12% w/w of dry powder mass through a 0.5 mm nozzle at 5–10 mL/min/kg. Impeller speed is maintained at 150–250 rpm with a chopper speed of 1000–1500 rpm. Granules are dried in a fluidised bed at inlet air temperature 45–60°C until loss-on-drying by USP 731 reaches 1.5–3.0%. Compression is performed on a rotary tablet press at 12–20 kN main compression force; hardness is adjusted to 50–80 N and disintegration time is tested by USP 701. Content uniformity of the finished tablets is assessed per USP 905; the acceptance value is not more than 15. Dissolution testing is performed in 900 mL phosphate buffer pH 6.8 at 50 rpm paddle speed using USP 711, with not less than 80% of marker released within 60 minutes for immediate-release tablets.

For capsule blends, the solution is adsorbed onto colloidal silicon dioxide or maltodextrin at a liquid-to-carrier ratio from 1:2 to 1:4; the loaded carrier is blended with magnesium stearate 0.25–0.5% w/w and filled on a semi-automatic capsule machine. Granules and premix intermediates are prepared by spray drying the solution onto a starch or dextrose carrier at inlet temperature 150–180°C and outlet temperature 70–90°C; particle size is controlled at D90 < 250 µm by USP 786. Flowability is measured by USP 1174; the compressibility index is controlled below 25% and Hausner ratio below 1.25 to ensure uniform filling into sachets and bulk containers. Production-scale fluidised-bed runs show the highest granule size variability during the first 10–15 minutes of spraying, particularly when atomisation pressure falls below 1.5 bar, which can produce a bimodal size distribution and require regranulation.

When Sterile Injectable or Perfusion Solution Forms Are Required

For sterile injectable and intramammary perfusion solutions, the bulk solution is first passed through 0.45 µm and then 0.22 µm sterilising-grade membrane filters. The pH is adjusted to 5.0–6.5 with tromethamine or sodium citrate; osmolality is adjusted to 280–320 mOsm/kg with sodium chloride or glycerol and verified by freezing-point depression per USP 785. The solution is filled into type I glass vials or multilayer plastic vials under nitrogen. When terminal moist heat sterilisation is used, the standard cycle is 121°C for 15 minutes, provided that formulation stability data support the cycle. If terminal sterilisation is not compatible, aseptic filtration and aseptic filling are required. The finished injection is tested for sterility by USP 71, bacterial endotoxin by USP 85, and particulate matter by USP 788. Filter compatibility studies with polyvinylidene fluoride and polyethersulfone membranes show that adsorption of chlorogenic acid is less than 5% when the solution is filtered at 20–25°C; filtration at 2–8°C may increase viscosity and reduce flow rate. Hold time after final filtration should not exceed 8 hours at controlled room temperature unless validated.

For intramammary infusion in lactating dairy cattle, the perfusion solution is typically diluted with sterile water for injection to a target chlorogenic acid concentration of 0.5–1.0 mg/mL and warmed to 35–38°C before administration through the teat canal using a single-use syringe. The solution must be free of visible particles and protected from light until use. Colour change during moist heat sterilisation is a known stability risk for polyphenol-containing botanical solutions; if the colour shifts from amber to dark brown, the content of chlorogenic acid may remain within assay limits, but oxidative polymers may increase turbidity and should be monitored by size-exclusion chromatography. Clinical field data for this specific botanical configuration is limited; the final dose, treatment interval, and withdrawal period must therefore be established in the approved veterinary product dossier or by prescription under national regulations.

Comparative Specification Cross-Check Against Conventional Shanzha Extract

Differences from crude Shanzha extract and from synthetic mammary preparations are primarily observed in standardisation, contaminant control, and formulation compatibility. Crude extracts often vary in chlorogenic acid and hyperoside content by up to ±30% between harvests and may require additional milling and solvent removal before formulation. The veterinary-grade solution is standardised in a closed extraction process, filtered through 0.2 µm membrane, and released with compendial residual solvent, heavy metal, and microbial limits. Compared with synthetic antibiotic intramammary preparations, the Shanzha API is not classified as an antibiotic and does not contain β-lactam, aminoglycoside, or tetracycline residues; its regulatory filing follows the botanical veterinary active substance pathway rather than the antimicrobial resistance risk pathway. Compared with other botanical polyphenol products, the Shanzha profile is distinguished by the presence of procyanidins and triterpenic acids, which influence astringency and pH-dependent solubility. Model SZ-MPS-VG-25 denotes the as-supplied solution-grade API. A spray-dried carrier variant, model SZ-MPS-VG-25-SD, is available for manufacturers requiring a free-flowing powder; it uses maltodextrin as carrier at 15–20% w/w API solids and has a moisture content of not more than 5% by USP 731.

Operational boundaries are defined by extract stability and excipient compatibility. The solution should not be combined with cationic polymers such as chitosan at pH values above 6.0, because polyphenolic constituents can form insoluble electrostatic complexes that clog sterilising filters. Contact with strong oxidising agents and concentrated mineral acids should be avoided due to rapid oxidative degradation of chlorogenic acid to quinone products. The lot should be stored in high-density polyethylene, glass, or 316L stainless steel; uncoated steel and aluminium are unsuitable for holding periods longer than 24 hours because of phenolic chelation and pitting corrosion. Exposure to relative humidity above 60% during open handling of adsorbed powders may accelerate moisture uptake and reduce blend flow; the powder should therefore be transferred under controlled relative humidity below 60%. For injection-grade processing, all water used for dilution must meet USP pharmaceutical water quality or the equivalent Ph. Eur. 0169 monograph for water for injections.